New Keytruda Approval Rekindles An Old Debate
Executive Summary
Approval for first-line BRAF+ patients puts Merck's Keytruda ahead of Bristol's Opdivo in melanoma, and in line to take share from BRAF/MEK combos, which are currently dominant in this patient population. Interactive timeline gives visual overview of immunotherapy approvals in key markets.
You may also be interested in...
Novartis' Growth Driver Tafinlar/Mekinist Picks Up New Melanoma, Thyroid Indications
New FDA labeling brings Tafinlar/Mekinist into adjuvant melanoma setting, but Bristol's competing Opdivo already has captured nearly 50% of the market and is approved regardless of genetic mutation.
New Melanoma Frontier Opens To Bristol's Opdivo And Novartis/Glaxo's BRAF/MEK Combo
Bristol's Opdivo and Novartis/GlaxoSmithKline's Tafinlar/Mekinist combo both performed well in early, post-surgical treatment of advanced melanoma in trials reported at ESMO, promising yet another revolution in the standard of care, but leaving Roche's Zelboraf/Cotellic in the dust.
PD-1 Deep Dive: Lung Cancer Market Braced For Change
Execs speculated during third-quarter earnings calls about the impact of FDA approval for Merck's Keytruda in first-line lung cancer and looked forward to readouts of combination studies, which could soon bring another market shake-up.